Aplastic Anemia

Aplastic anemia is a rare disorder in which damage to blood-forming stem cells leaves the bone marrow unable to produce sufficient blood cells. Despite its name, it involves more than anemia: reduced production of red blood cells, white blood cells, and platelets can cause fatigue, infection, and bleeding. Its characteristic findings are low blood cell counts and a markedly depleted, or hypocellular, marrow. (nhlbi.nih.gov)

Most acquired cases involve an immune system attack on hematopoietic cells, although an initiating cause often remains unidentified. Inherited marrow failure disorders can produce a similar presentation and require distinction from acquired disease. Diagnosis combines blood testing, marrow examination, and exclusion of alternative conditions. Treatment includes supportive care, immunosuppressive medicines, drugs that stimulate blood formation, and hematopoietic stem cell transplantation. These approaches have substantially improved outcomes, while relapse and the development of abnormal blood-cell clones remain important long-term concerns. (ncbi.nlm.nih.gov)

Definition and Disease Boundaries

Aplastic anemia is a disorder of blood-cell production characterized by reduced blood-cell counts in the circulation and a hypocellular bone marrow, without an abnormal infiltrate or significant marrow fibrosis. “Hypocellular” means that blood-forming tissue is markedly depleted, leaving predominantly fatty spaces rather than the expected complement of developing blood cells. The characteristic blood finding is pancytopenia—reduction of red cells, white cells, and platelets—although all three lineages need not be equally affected. The 2024 British Society for Haematology guideline requires at least two of three abnormalities: hemoglobin concentration below $100\,\mathrm{g/L}$, platelets below $50 \times 10^{9}/\mathrm{L}$, or neutrophils below $1.5 \times 10^{9}/\mathrm{L}$. These diagnostic thresholds are distinct from the criteria defining severe disease. (onlinelibrary.wiley.com)

Despite its name, the disorder is not confined to anemia. Its central defect is a profound shortage of hematopoietic stem cells and progenitor cells, which normally sustain several blood-cell lineages. Their depletion reduces the production of red blood cells, granulocytes—including neutrophils—and platelets. Thus, anemia is one component of a broader failure of blood formation, rather than the defining lesion by itself. This is fundamentally a production disorder: the marrow cannot adequately replenish circulating cells, rather than merely losing otherwise normally produced cells through bleeding or accelerated destruction. (pubmed.ncbi.nlm.nih.gov)

The word “aplastic” does not require the marrow to be completely empty. Residual islands of blood formation may persist, and hypocellularity may be patchy. Conversely, low blood counts alone do not establish the disease. The marrow appearance must fit the diagnosis, and competing explanations must be excluded. In particular, hypoplastic myelodysplastic syndrome can also produce cytopenias with a sparsely cellular marrow. Pure red-cell aplasia differs because its production defect predominantly affects the erythroid lineage rather than the multilineage pattern characteristic of aplastic anemia. (onlinelibrary.wiley.com)

An aplastic marrow is a phenotype, not a complete statement of cause. Similar peripheral-blood and marrow findings can arise from acquired disease or an inherited marrow-failure syndrome. Acquired aplastic anemia is more common; most cases lack an identifiable initiating cause and are termed idiopathic. Immune-mediated injury to marrow stem cells is central to the prevailing explanation of acquired disease. “Idiopathic” therefore describes the absence of an established initiating cause, not the absence of a biological mechanism. (niddk.nih.gov)

Terminology varies with context. Some specialist classifications reserve “aplastic anemia” for acquired, immunologically mediated disease and classify inherited disorders separately. In broader descriptive usage, inherited conditions such as Fanconi anemia and telomere biology disorders can produce an aplastic-anemia presentation. These inherited conditions may first become apparent in adulthood; age at presentation alone does not establish an acquired origin. Distinguishing the marrow phenotype from its underlying disease is therefore essential to defining the diagnostic boundary. (pmc.ncbi.nlm.nih.gov)

Epidemiology and Population Patterns

European studies place the annual incidence of aplastic anemia at approximately 2–3 new cases per million people. A Swedish nationwide study of diagnoses made during 2000–2011 identified 257 confirmed cases of acquired disease, yielding an incidence of 2.35 per million person-years, with a 95% confidence interval of 2.06–2.64. Case identification combined national registry searches with review of medical records rather than accepting diagnostic codes alone. These figures describe newly diagnosed disease in a defined population, not the proportion of hematology patients who have aplastic anemia. (haematologica.org)

Higher rates have been reported in East Asia. A Chinese cooperative survey conducted during 1986–1988 covered 44 study areas across 21 provinces, municipalities, and autonomous regions. It identified 387 new cases during more than 52 million person-years of observation, corresponding to 7.4 cases per million annually; the reported 95% confidence interval was 6.7–8.2 per million. This is a historical estimate from the surveyed populations, rather than a measurement of present-day incidence throughout East Asia. (pubmed.ncbi.nlm.nih.gov) Evidence from Southeast Asia also demonstrates substantial geographic variation: a standardized Thai population study identified 374 cases and estimated annual rates of 3.9 per million in Bangkok, 3.0 in Songkla, and 5.0 in Khonkaen. Its methods and case definition matched those used in the International Agranulocytosis and Aplastic Anemia Study in Europe and Israel, strengthening the comparison between regions. (pubmed.ncbi.nlm.nih.gov)

The age-specific incidence often has a bimodal distribution, with one peak in adolescents or young adults and another in older adults. In Sweden, incidence was 2.87 per million annually at ages 15–20 and 4.36 per million above age 60; the median age at diagnosis was 60 years. Thus, a young-adult incidence peak does not imply that most patients are young. The Swedish pattern was more distinctly bimodal in males, whereas female incidence rose more steadily toward older age. (pmc.ncbi.nlm.nih.gov) The pattern is not universal: Bangkok showed peaks at ages 15–24 and above 60, while the rural Thai study regions showed a more continuous increase with age. Age distributions therefore need to be interpreted within the population studied rather than treated as fixed diagnostic characteristics. (pubmed.ncbi.nlm.nih.gov)

Incidence must be distinguished from prevalence. Incidence counts new cases arising during a specified interval, with rates expressed here per million person-years; prevalence counts existing cases in a population at a specified time or during a specified period. The European estimate of 2–3 cases per million annually consequently does not mean that only 2–3 people per million are living with the disease. Prevalence reflects both the occurrence of new disease and its duration: longer survival with persistent disease can increase prevalence without any increase in incidence. Comparisons of population burden must therefore specify which measure is being reported and the period to which it applies. (cdc.gov)

Causes and Associated Conditions

Most acquired aplastic anemia is described as idiopathic: no initiating exposure or underlying cause is identified. This does not mean that the process causing marrow failure is entirely unknown. Injury mediated by the immune system is central to many acquired cases, but the event that initiates the attack on blood-forming stem cells often remains unidentified. Acquired disease is more common than inherited marrow-failure syndromes; the distinction concerns the origin of the stem-cell injury, rather than the appearance of the aplastic bone marrow alone. (niddk.nih.gov)

Medicines can produce marrow injury through different processes. Cytotoxic chemotherapy can directly damage blood-forming cells, whereas some other medicines are associated with rare, unpredictable reactions. Chloramphenicol illustrates an important distinction: its prescribing information describes both reversible, dose-related marrow suppression and a separate, potentially irreversible aplastic process that may appear weeks or months after treatment. Carbamazepine also carries a warning about aplastic anemia, although most decreases in white blood cells reported during its use do not progress to aplastic anemia. These recognized adverse reactions do not establish that a particular medicine caused every case occurring after exposure; chronology alone cannot distinguish a drug reaction from coincidental idiopathic disease. (nhlbi.nih.gov)

Toxic exposures include benzene, an established marrow toxicant associated with reduced blood-cell production and aplastic anemia. Chronic occupational exposure is a recognized setting, but exposure circumstances and intensity matter: a general history of contact with chemicals is not equivalent to demonstrated causation. Ionizing radiation can also damage blood-forming tissue, including in the context of radiation treatment. Toxic or treatment-related marrow suppression therefore needs to be distinguished from acquired immune-mediated aplasia, even though both can result in depletion of marrow cells and impaired blood-cell formation. (atsdr.cdc.gov)

Hepatitis-associated aplastic anemia develops after an episode of acute liver inflammation and does not require identification of a hepatitis virus. In a 1997 National Institutes of Health study, K. E. Brown and colleagues examined 10 patients referred between 1990 and 1996. All had negative serologic tests for hepatitis A, B, and C, and hepatitis C viral RNA was undetectable in every patient. Activated CD8 T cells were present, supporting an immune-mediated association rather than establishing direct infection of marrow stem cells by a known hepatitis virus. Thus, “hepatitis-associated” describes the clinical sequence; it is not synonymous with hepatitis B– or hepatitis C–induced marrow failure. (pubmed.ncbi.nlm.nih.gov)

Inherited conditions can produce a similar aplastic phenotype through defects intrinsic to cells. Fanconi anemia involves defective DNA repair, particularly the response to interstrand cross-links that obstruct DNA replication. Accumulating damage is especially harmful to rapidly dividing marrow cells, impairing production of all blood-cell lineages. Telomere biology disorders, including dyskeratosis congenita, instead involve inadequate maintenance of chromosome ends. Pathogenic variants in genes such as TERC or TERT can impair telomerase function, allowing telomeres to become critically short and limiting cellular renewal. Importantly, TERC-associated disease may present as apparently isolated aplastic anemia without conspicuous nail, skin, or oral abnormalities. Inherited marrow failure is therefore not confined to patients with an obvious congenital syndrome. (medlineplus.gov)

Stem Cell Injury and Immune Mechanisms

Depletion of hematopoietic stem and progenitor cells reduces the marrow’s capacity to sustain blood-cell production. Stem cells normally maintain themselves through self-renewal while supplying progenitors that generate red cells, white cells, and platelets. Injury at this shared upstream compartment therefore impairs several cell lineages simultaneously, rather than selectively reducing red-cell production. In acquired immune-mediated disease, the defect includes both destruction of blood-forming cells and suppression of the surviving cells’ proliferation and differentiation; it is not simply accelerated destruction of mature circulating cells. Experimental studies have identified inflammatory signaling capable of inhibiting progenitor growth and promoting cell death. (pmc.ncbi.nlm.nih.gov)

Autoreactive cytotoxic T cells, particularly CD8-positive populations, are central to the prevailing model of acquired disease. Their recognition of targets on hematopoietic cells can produce direct cytotoxic injury, while released cytokines, including interferon-gamma and tumor necrosis factor-alpha, inhibit hematopoiesis. These signals can increase expression of the Fas death receptor on CD34-positive stem and progenitor cells, making them more susceptible to programmed cell death. In a 1997 study, T. Sato and colleagues demonstrated cytokine-induced increases in Fas expression on human marrow CD34-positive cells. These experiments establish plausible injury pathways without implying that every pathway contributes equally in every patient. (pmc.ncbi.nlm.nih.gov)

Evidence for immune-mediated suppression comes from culture experiments, clinical responses to immunosuppression, and the genetic characteristics of surviving hematopoietic clones. In 1976, W. A. Kagan and colleagues reported that removing lymphocytes from an affected patient’s marrow restored early myeloid differentiation in culture; coculturing the patient’s marrow with normal marrow transferred the suppressive effect. More recent evidence concerns loss of particular HLA class I molecules, which present peptides to cytotoxic T cells. A 2011 study identified acquired loss of one HLA haplotype through copy-number-neutral loss of heterozygosity on chromosome 6p. The preferential survival of these cells supports selection for escape from HLA-restricted immune attack. However, the initiating antigen—or combination of antigens—recognized by pathogenic T cells remains unresolved. (pubmed.ncbi.nlm.nih.gov)

A related form of clonal selection links acquired marrow failure with paroxysmal nocturnal hemoglobinuria (PNH). PNH clones usually originate from a hematopoietic stem cell carrying an acquired, somatic mutation in PIGA, an X-linked gene required for synthesis of glycosylphosphatidylinositol (GPI) anchors. Junji Takeda and colleagues demonstrated this molecular defect in 1993. Descendants of the affected stem cell lack, or have reduced amounts of, GPI-anchored surface proteins. PIGA-mutant cells are thought to gain a relative survival advantage in an immune-attacked marrow, although the precise mechanism of their escape is not fully established. This represents selection within a depleted stem-cell population, not proof that the mutation itself caused the original marrow failure. (pubmed.ncbi.nlm.nih.gov)

A detectable PNH clone is not synonymous with clinically hemolytic PNH. Sensitive flow cytometry can identify small GPI-deficient populations in patients whose dominant problem remains inadequate blood-cell production, without overt hemolysis. In classical PNH, loss of the GPI-anchored complement regulators CD55 and CD59 leaves red cells vulnerable to complement-mediated destruction, and clinically significant disease can include thrombosis. Small clones associated with marrow failure commonly lack these manifestations; clone size, biochemical evidence of hemolysis, and clinical features must therefore be distinguished. The proportion of GPI-deficient granulocytes also need not equal the red-cell proportion, because affected red cells can be selectively destroyed and donor red cells can dilute the measured population after transfusion. (pmc.ncbi.nlm.nih.gov)

Clinical Manifestations

Presentation may be rapid or develop gradually, with fatigue, bleeding, or infection becoming the dominant initial problem. These manifestations reflect the particular blood-cell lineages affected: reduced red-cell production causes anemia, platelet depletion impairs control of bleeding, and reduced white-cell production weakens resistance to infection. The three groups of manifestations need not be equally prominent in an individual. Mild disease may produce few or no symptoms, whereas more extensive marrow failure can present with several complications simultaneously. (nhlbi.nih.gov)

Reduced production of red blood cells lowers the amount of circulating hemoglobin available to transport oxygen. The resulting reduction in oxygen delivery produces fatigue, weakness, pallor, dizziness, and shortness of breath. Physical activity may become difficult because working tissues require more oxygen than the blood can readily supply. A rapid heartbeat or palpitations may accompany the anemia; severe anemia places additional demands on the cardiovascular system and can contribute to heart failure. These are consequences of insufficient oxygen-carrying capacity rather than evidence that the disorder affects red cells alone. (nhlbi.nih.gov)

Thrombocytopenia, or a reduced platelet count, limits the formation of the initial platelet plug that normally helps stop bleeding at damaged blood vessels. Common manifestations include easy bruising and petechiae—small, flat red or purple spots caused by bleeding into the skin. Mucosal bleeding may appear as recurrent nosebleeds, bleeding gums, or unusually heavy menstrual bleeding. Blood in the stool is another possible manifestation. This pattern differs from anemia-related symptoms: conspicuous bruising or bleeding may occur even when tiredness or breathlessness is not the main complaint. (niddk.nih.gov)

Bleeding can extend beyond visible skin and mucosal findings. Marked platelet depletion can permit spontaneous internal hemorrhage, and uncontrolled bleeding is a potentially life-threatening complication. External bruising therefore represents only one part of the bleeding phenotype; the clinical consequences depend on the location and extent of hemorrhage. Blood loss can also compound the anemia already produced by deficient marrow output. (niddk.nih.gov)

Infection susceptibility is especially associated with neutropenia, a shortage of neutrophils, which are white blood cells involved in defending against infection. Infections may occur more readily, persist longer, or become severe when white-cell production is markedly reduced. Fever may be part of the presentation, alongside other manifestations of infection. Profound neutropenia increases the risk that an infection will progress to sepsis, a life-threatening systemic complication. Thus, a patient whose most evident symptoms are infection and fever may have a different clinical presentation from one whose principal manifestations are pallor and exertional breathlessness, even though both arise from failure of blood-cell production. (together.stjude.org)

Diagnostic Evaluation and Differential Diagnosis

The initial complete blood count includes a white-cell differential, platelet count, and absolute reticulocyte count. Reduced reticulocytes—immature red cells—indicate inadequate marrow production despite anemia. Multiple cell lines are usually depressed, although early disease may present with isolated thrombocytopenia. Blood-film examination assesses cell morphology and looks for blasts or dysplastic cells suggesting another disorder; macrocytosis alone does not establish myelodysplasia. Biochemical investigations include vitamin B12, folate, liver-function tests, and infection testing selected to identify associated conditions or alternative explanations. Documented vitamin deficiencies must be addressed before the final diagnosis is established. (onlinelibrary.wiley.com)

Both a bone marrow aspirate and a core, or trephine, biopsy are required. The aspirate permits examination of residual precursors, while the core shows overall cellularity and tissue architecture. Typical findings are markedly reduced hematopoietic tissue, prominent fat spaces, and depleted granulocytic precursors and megakaryocytes. An adequate core is important because cellularity can be patchy, and normally hypocellular subcortical tissue can give a misleading impression. An abnormal infiltrate, increased blasts, or substantial fibrosis argues against uncomplicated aplastic anemia. (onlinelibrary.wiley.com)

Cytogenetic analysis and targeted DNA sequencing help characterize clonality, but neither an abnormal chromosome result nor a somatic mutation automatically establishes myelodysplastic syndrome (MDS). For example, trisomy 8 and deletion 13q can occur in otherwise typical aplastic anemia. The 2024 British Society for Haematology guideline therefore emphasizes integrated interpretation of morphology and genetics rather than mutation results in isolation. Hypoplastic MDS is favored by dysplastic granulocytes or megakaryocytes, increased blasts, and other concordant abnormalities; erythroid dysplasia alone is insufficient to distinguish the two. Hypocellular leukemia is distinguished through identification and characterization of its abnormal blast population. (onlinelibrary.wiley.com)

Peripheral-blood flow cytometry screens for paroxysmal nocturnal hemoglobinuria (PNH) clones. High-sensitivity assays detect deficient glycosylphosphatidylinositol-anchored proteins using FLAER and lineage-specific markers in granulocytes and monocytes, together with red-cell markers such as CD59. Testing more than one lineage matters because transfused red cells and shortened survival of PNH red cells can distort the apparent clone size. The 2021 North American Pediatric Aplastic Anemia Consortium consensus specifies assays capable of detecting clones as small as 0.01%. A small clone supports acquired immune-mediated marrow failure but does not itself establish clinically hemolytic PNH. (onlinelibrary.wiley.com)

Inherited-disease investigations are guided by age, physical findings, and personal and family histories; absence of obvious congenital abnormalities does not exclude an inherited disorder. Fanconi anemia testing measures chromosome breakage after exposure to diepoxybutane or mitomycin C. When blood testing is negative despite strong suspicion, cultured skin fibroblasts can reveal disease masked by blood-cell mosaicism. Age-adjusted lymphocyte telomere measurement by flow-FISH screens for telomere biology disorders, with very short results prompting further genetic evaluation. Germline sequencing complements these functional tests rather than replacing them. (onlinelibrary.wiley.com)

Pure red-cell aplasia differs by selectively suppressing erythropoiesis: severe anemia and reticulocytopenia accompany near-absence of marrow erythroblasts, while leukocyte and platelet counts are generally preserved. A 2004 expert consensus described a characteristic absolute reticulocyte count below $10 \times 10^{9}/\mathrm{L}$. This lineage-selective pattern contrasts with the broader precursor depletion of aplastic anemia, even when anemia dominates the presenting blood count. (onlinelibrary.wiley.com)

Severity Classification

Aplastic anemia is classified as non-severe, severe, or very severe using the modified Camitta criteria. These combine bone marrow cellularity with absolute peripheral blood counts, rather than grading the disease by symptoms or hemoglobin concentration alone. The British Society for Haematology’s 2024 guideline specifies that severe disease requires both qualifying marrow hypocellularity and sufficiently reduced counts in at least two of three blood-cell categories; neither component establishes severe disease independently. (onlinelibrary.wiley.com)

Severe aplastic anemia (SAA) requires marrow cellularity below $25\%$, or cellularity of $25\%–50\%$ with less than $30\%$ residual hematopoietic cells, together with at least two of the following peripheral blood abnormalities:

• Absolute neutrophil count below $0.5 \times 10^{9}/\mathrm{L}$, equivalent to 500 cells per microliter.
• Platelet count below $20 \times 10^{9}/\mathrm{L}$, equivalent to 20,000 platelets per microliter.
• Absolute reticulocyte count below $60 \times 10^{9}/\mathrm{L}$, equivalent to 60,000 reticulocytes per microliter, using an automated reticulocyte count.

The reticulocyte threshold is an absolute count, not a percentage of circulating red cells. These same numerical criteria appear in the 2024 evidence-based pediatric recommendations. (onlinelibrary.wiley.com)

Very severe aplastic anemia (VSAA) meets the criteria for severe disease but has an absolute neutrophil count below $0.2 \times 10^{9}/\mathrm{L}$, or 200 cells per microliter. The lower neutrophil threshold is an additional distinction within severe marrow failure, not a substitute for the other requirements. As an illustration of applying the criteria, marrow cellularity of $15\%$, platelets of $12 \times 10^{9}/\mathrm{L}$, and neutrophils of $0.3 \times 10^{9}/\mathrm{L}$ qualify as severe disease regardless of whether reticulocytes meet their threshold. With otherwise identical findings and neutrophils of $0.1 \times 10^{9}/\mathrm{L}$, the classification is very severe. (onlinelibrary.wiley.com)

Non-severe aplastic anemia (NSAA) denotes established aplastic anemia that does not fulfill the severe or very severe criteria. It is therefore a residual category, not a single narrow range of blood counts. Markedly hypocellular marrow does not automatically establish severe disease if fewer than two peripheral blood thresholds are met. Conversely, a low neutrophil count alone is insufficient. “Non-severe” also does not mean normal blood production or absence of clinically important cytopenias. (onlinelibrary.wiley.com)

Hemoglobin is absent from the three peripheral blood thresholds used to define severe disease. The classification instead incorporates neutrophil and platelet deficits, relevant to infection and hemorrhage, alongside reticulocytes as a measure of red-cell production. Consequently, profound anemia does not by itself establish SAA, while SAA can be established through the neutrophil and platelet criteria without meeting the reticulocyte threshold. These categories describe the extent of marrow failure across blood-cell lineages rather than simply the severity of reduced oxygen-carrying capacity. (pmc.ncbi.nlm.nih.gov)

Supportive Care and Treatment Context

Blood transfusions temporarily replace missing circulating cells: red-cell concentrates improve oxygen-carrying capacity and relieve symptomatic anemia, while platelet concentrates prevent or control bleeding. Neither restores the depleted stem-cell population or normal hematopoiesis. Transfusion requirements therefore may persist while disease-directed treatment takes effect. Repeated red-cell transfusions can cause iron accumulation and organ injury; repeated exposure to donor antigens can also produce antibodies that impair subsequent transfusion responses. These complications make transfusion history, antibody testing, and assessment of iron burden part of continuing care. (niddk.nih.gov)

Transfusion thresholds depend on clinical circumstances rather than a blood count alone. The 2024 British Society for Haematology guideline describes prophylactic platelet transfusion below $10 \times 10^{9}/L$ for stable patients receiving active treatment in hospital, but distinguishes this setting from asymptomatic chronic thrombocytopenia, where routine prophylactic transfusion is not necessarily used. Bleeding and procedures alter transfusion requirements. Patients who develop immune-mediated platelet refractoriness may require platelets matched for human leukocyte antigens, the human form of the major histocompatibility complex. (onlinelibrary.wiley.com) A 2024 expert consensus also specifies leukoreduced, irradiated red-cell and platelet components in severe aplastic anemia care. (pmc.ncbi.nlm.nih.gov)

Infection prevention addresses both prolonged neutropenia and the additional immune impairment caused by treatment. The American Society of Hematology’s 2026 guideline conditionally supports antibacterial and mold-active antifungal prophylaxis when neutrophils are below $0.5 \times 10^{9}/L$, while explicitly rating the supporting evidence as very low certainty. (pmc.ncbi.nlm.nih.gov) Following lymphocyte-depleting treatment, prophylaxis may additionally target Pneumocystis jirovecii pneumonia and herpesvirus reactivation; examples include atovaquone or pentamidine for the former and acyclovir for the latter. (pmc.ncbi.nlm.nih.gov) Suspected infection requires prompt assessment and antimicrobial treatment: profound neutropenia can permit rapid progression to invasive infection and sepsis. (onlinelibrary.wiley.com)

Treatment pathways reflect disease severity, age, comorbidities, and the availability of a compatible donor. Some stable non-severe cases undergo observation rather than immediate disease-directed treatment. (niddk.nih.gov) For severe acquired disease, the principal pathways are immunosuppressive treatment and allogeneic hematopoietic stem cell transplantation. The 2026 American Society of Hematology guideline conditionally favors matched-sibling transplantation over immunosuppression for patients younger than 40, but favors immunosuppression in those older than 40; these comparisons rest on very-low-certainty evidence. Such age categories organize evidence rather than establish absolute eligibility limits, because organ function, comorbidities, and donor characteristics also influence treatment risk. (pmc.ncbi.nlm.nih.gov)

Children require pediatric treatment pathways, including consideration of inherited marrow failure rather than assuming acquired immune-mediated disease. (pmc.ncbi.nlm.nih.gov) Older adults require particular attention to treatment fitness and coexisting illness. During pregnancy, maternal bleeding risk, fetal considerations, and restrictions on disease-directed treatments make supportive care especially important; the 2024 British guideline specifies a platelet target above $20 \times 10^{9}/L$, based on expert opinion. Inherited syndromes, including Fanconi anemia and telomere biology disorders, require distinct management because associated abnormalities outside the marrow affect clinical assessment and treatment planning. (onlinelibrary.wiley.com)

Immunosuppression and Blood-Formation–Stimulating Medicines

Antithymocyte globulin (ATG) and cyclosporine have complementary roles in acquired, immune-mediated disease: ATG depletes and modifies the activity of lymphocytes, including T cells, whereas cyclosporine inhibits T-cell activation and production of interleukin-2, a signaling molecule that supports immune responses. ATG is an animal-derived preparation of antibodies against human thymocytes, administered intravenously as a short course; oral cyclosporine provides more sustained immunosuppression. Their purpose is to reduce immune-mediated injury so that surviving stem and progenitor cells can restore blood formation, rather than to replace the blood-forming system. ATG formulations are not clinically interchangeable: in a 2011 randomized trial led by Phillip Scheinberg, six-month hematologic response was 68% with horse ATG plus cyclosporine and 37% with rabbit ATG plus cyclosporine in previously untreated severe disease. (nejm.org)

Eltrombopag acts principally through stimulation of blood-cell production rather than suppression of the immune attack. It is an oral, small-molecule agonist of the thrombopoietin receptor, also called MPL or c-MPL. Although thrombopoietin is closely associated with platelet production, its receptor also functions in hematopoietic stem and progenitor cells; stimulation can therefore support recovery of red cells and neutrophils as well as platelets. In a 2012 study of 25 patients with disease refractory to immunosuppression, 11 patients—44%—met response criteria in at least one lineage after 12 weeks of eltrombopag. Some subsequently developed responses in additional lineages, demonstrating that its effects were not confined to platelet counts. (nejm.org)

The 2022 RACE randomized controlled trial, reported by Régis Peffault de Latour and colleagues, compared horse ATG plus cyclosporine with the same regimen plus eltrombopag. Conducted at 24 centers in six European countries, its confirmed-disease population comprised 197 patients with previously untreated severe or very severe disease. At six months, overall hematologic response was 68% with eltrombopag versus 41% without it, an absolute difference of 27 percentage points. Overall response combined complete and partial responses; importantly, the trial required transfusion independence for partial response. Thus, the result represented clinically meaningful recovery of blood production, but did not mean that 68% of participants had normal blood counts or had been cured. (nejm.org)

Response remains a graded and time-dependent outcome. A partial response can remove the need for blood transfusions while leaving persistent cytopenias; complete response requires more extensive count recovery according to the study’s specified thresholds. Refractory disease denotes failure to achieve an adequate response after treatment, commonly assessed at six months in ATG-based trials. Relapse differs from initial nonresponse: blood counts deteriorate after an earlier response, sufficiently to require renewed treatment. In a separate NIH phase 2 study reported by Bhavisha Patel and colleagues in 2022, the estimated four-year cumulative relapse rate was 39% among responding patients who received cyclosporine maintenance. Relapses clustered after treatment reduction or discontinuation, and approximately two-thirds of retreated patients responded to therapeutic-dose cyclosporine with or without eltrombopag. These figures describe that cohort, not the randomized RACE comparison. (nejm.org)

Hematologic response, survival, and cure are therefore distinct endpoints. A response rate measures blood-count recovery at a specified assessment; overall survival measures whether patients remain alive, including those subsequently receiving additional medicines or stem cell transplantation. Even substantial recovery after immunosuppression may remain treatment-dependent or be followed by relapse. Trials consequently assess durability and subsequent treatment requirements separately from the initial response percentage. (nejm.org)

Hematopoietic Stem Cell Transplantation

Allogeneic hematopoietic stem cell transplantation replaces the deficient blood-forming system with stem cells from another person. The cells are infused intravenously and establish donor-derived hematopoiesis in the recipient’s bone marrow, potentially restoring red-cell, white-cell, and platelet production. Unlike transfusion support, successful transplantation provides a self-renewing source of blood cells and can cure the marrow failure. Its principal role is in severe or very severe disease, either as initial treatment in selected patients or after failure of immunosuppressive therapy. (nhlbi.nih.gov)

Donor selection centers on compatibility at human leukocyte antigen (HLA) loci, part of the major histocompatibility complex, rather than simply on blood-group compatibility. An HLA-identical sibling is an established donor option; a suitably matched unrelated volunteer provides another route when no matched sibling is available. Alternative sources include HLA-mismatched unrelated donors, haploidentical relatives sharing one inherited HLA haplotype, and umbilical cord blood. These approaches require different strategies for controlling rejection and immune complications. The 2025 European Society for Blood and Marrow Transplantation (EBMT) recommendations recognize promptly available, well-matched unrelated transplantation as a first-line option for selected children, while alternative-donor transplantation has an established role after failed immunosuppression. (ebmt.org)

Before infusion, a conditioning regimen suppresses the recipient’s immune response sufficiently to permit donor-cell establishment. In acquired aplastic anemia, the purpose is principally to overcome immune barriers, not to eradicate a malignant cell population. Regimens commonly use cyclophosphamide, sometimes combined with fludarabine, and lymphocyte-depleting agents such as antithymocyte globulin or alemtuzumab. Selected unrelated- or alternative-donor protocols also incorporate low-dose total-body irradiation; irradiation is not routinely required for matched-sibling transplantation. Bone marrow is generally preferred over mobilized peripheral blood because of its lower risk of chronic graft-versus-host disease. In a 2012 registry study of 1,886 matched-sibling transplants performed during 1999–2009, chronic graft-versus-host disease occurred in 11% of marrow recipients versus 22% of peripheral-blood recipients. These observational results describe that historical cohort, not a universal contemporary risk. (ncbi.nlm.nih.gov)

Engraftment means that donor cells establish sustained blood-cell production. Recovery is assessed through blood counts and chimerism testing, which measures the proportions of donor- and recipient-derived cells. Primary graft failure denotes failure to establish adequate hematopoietic recovery; secondary graft failure occurs after initial recovery has been achieved. Immune rejection is one mechanism of graft failure, but the terms are not interchangeable. Persistent or recurrent cytopenias can leave the recipient dependent on transfusions and vulnerable to infection, and may necessitate further cellular treatment or another transplant. (ncbi.nlm.nih.gov)

Graft-versus-host disease (GVHD) is a different immune complication: donor immune cells attack recipient tissues. Unlike transplantation for leukemia, transplantation for uncomplicated aplastic anemia does not require a beneficial graft-versus-leukemia effect. GVHD prevention therefore has particular importance; approaches include cyclosporine with methotrexate and, especially in haploidentical transplantation, post-transplant cyclophosphamide. Conditioning, delayed immune reconstitution, and treatment of GVHD also increase susceptibility to bacterial, fungal, and viral infections. Antimicrobial prevention, surveillance, and treatment remain important after blood counts begin to recover. (haematologica.org)

Transplant outcomes cannot be represented by one success percentage. Recipient age, comorbidities, infection status, previous treatment, and the interval between diagnosis and transplantation influence risk. Donor compatibility, graft source, conditioning, and GVHD-prevention protocols also matter. The 2025 EBMT recommendations explicitly assess age alongside comorbidities and transplant characteristics rather than treating donor availability alone as sufficient. Published results consequently require specification of the patient population, donor approach, treatment era, follow-up duration, and endpoint—particularly whether the reported outcome is survival alone or survival without graft failure or substantial GVHD. (nature.com)

Outcomes, Long-Term Follow-Up, and Research

Outcome measures describe different aspects of recovery. Overall survival measures survival from a specified starting point, regardless of subsequent relapse or additional treatment. Hematologic recovery concerns improvement in blood-cell production and may be partial or complete according to protocol-defined count thresholds. Transfusion independence means that red-cell or platelet support is no longer required; it does not necessarily imply normal counts or freedom from medication. Event-free survival additionally captures treatment failure, but its definition varies between studies. In the 2022 RACE randomized trial, events included nonresponse at six months, transplantation, additional aplastic-anemia treatment, relapse, clonal evolution, or death. Two-year event-free survival was 46% with eltrombopag plus immunosuppression versus 34% with immunosuppression alone: these figures are not overall-survival or cure rates. (pubmed.ncbi.nlm.nih.gov)

Late complications remain possible after an initial response. Bhavisha Patel and colleagues’ phase 2 follow-up study, published in 2022, included 178 patients receiving immunosuppression and eltrombopag, with a median follow-up of four years. The estimated four-year cumulative relapse rate was 39% among responders receiving cyclosporine maintenance. Relapses clustered after cyclosporine dose reduction and eltrombopag withdrawal at six months, and after cyclosporine discontinuation at two years; approximately two-thirds of retreated patients responded again. Cytogenetic clonal evolution occurred in 15% of all treated patients, whereas the narrower high-risk category—myeloid malignancy or a chromosome 7 abnormality—occurred in 5.7%. Thus, the broader 15% figure should not be interpreted as the rate of leukemia. Comparison with a historical cohort found no increased frequency of high-risk evolution, although events occurred earlier; this was not a randomized long-term comparison. (pmc.ncbi.nlm.nih.gov)

Long-term surveillance distinguishes recurrent marrow failure from paroxysmal nocturnal hemoglobinuria (PNH) expansion and evolution to myelodysplastic syndrome or acute myeloid leukemia. Serial complete blood counts document declining or sustained production; marrow morphology and cytogenetic assessment identify dysplasia, increasing blasts, or emerging chromosome abnormalities. Peripheral-blood flow cytometry measures PNH populations, including clones that become detectable after diagnosis. Clone size is interpreted alongside hemolysis and clinical findings: expansion of a PNH population is not equivalent to malignant transformation. Surveillance schedules vary with treatment, count trends, and previous abnormalities rather than following one universal interval. (fredhutch.org)

Therapeutic development moved from immune suppression alone toward combined immune suppression and stem-cell stimulation. A 1977 report by Bruno Speck, Éliane Gluckman, and colleagues treated 29 patients with antilymphocyte globulin, with or without subsequent marrow infusion, forming part of the late-1970s development of globulin-based treatment. Cyclosporine combinations entered multicenter trials during the 1980s: a German study enrolling patients in 1986–1989, published in 1991, reported three-month responses of 65% with cyclosporine added to globulin and methylprednisolone, versus 39% without cyclosporine. In 2012, Matthew Olnes and colleagues reported responses in at least one blood-cell lineage in 11 of 25 patients with refractory disease receiving eltrombopag. Front-line combination studies followed in 2017 and the randomized RACE study in 2022. (pubmed.ncbi.nlm.nih.gov)

Research now connects marrow-cell states with the behavior of surviving hematopoietic and immune clones. A 2025 study by Zongming Wu and colleagues analyzed marrow from 20 patients using single-cell RNA sequencing, immune-receptor sequencing, and complementary cytometry before and after treatment. It identified treatment-associated changes in inflammatory signaling and heterogeneous T-cell clonal responses; these observations generate mechanistic hypotheses rather than validated treatment-selection tests. Separately, longitudinal DNA sequencing investigates why some mutated hematopoietic populations remain stable while others expand. Detection of a somatic mutation alone does not establish myelodysplasia or predict an individual outcome. Longer comparative follow-up addresses whether earlier responses translate into durable treatment-free recovery, fewer malignant complications, and better quality of life, rather than simply higher short-term response rates. (pubmed.ncbi.nlm.nih.gov)

References

1. Acquired aplastic anemiapubmed.ncbi.nlm.nih.gov
2. Symptoms & Causes of Aplastic Anemia & Myelodysplastic Syndromesniddk.nih.gov
3. The clinical and laboratory evaluation of patients with suspected hypocellular marrow failurepmc.ncbi.nlm.nih.gov
4. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000–2011haematologica.org
5. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000–2011pmc.ncbi.nlm.nih.gov
6. Incidence survey of aplastic anemia in Chinapubmed.ncbi.nlm.nih.gov
7. Regional patterns in the incidence of aplastic anemia in Thailand. The Aplastic Anemia Study Group.pubmed.ncbi.nlm.nih.gov
8. Epidemiology of aplastic anemia in Thailand. Thai Aplastic Anemia Study Grouppubmed.ncbi.nlm.nih.gov
9. Incidence - Health, United Statescdc.gov
10. Principles of Epidemiology | Lesson 3 - Section 2archive.cdc.gov
11. Anemia - Aplastic Anemia | NHLBI, NIHnhlbi.nih.gov
12. Chloramphenicol Sodium Succinate for Injection, USPdailymed.nlm.nih.gov
13. DailyMed - Carbamazepine Extended-Release Tablets, USP 100 mg, 200 mg, 400 mgdailymed.nlm.nih.gov
14. Benzene: Relevance to Public Healthatsdr.cdc.gov
15. Benzene: Systemic Agent | NIOSH | CDCcdc.gov
16. In Brief: Your Guide to Anemianhlbi.nih.gov
17. Hepatitis-associated aplastic anemiapubmed.ncbi.nlm.nih.gov
18. Fanconi anemia: MedlinePlus Geneticsmedlineplus.gov
19. TERC gene: MedlinePlus Geneticsmedlineplus.gov
20. TERT gene: MedlinePlus Geneticsmedlineplus.gov
21. HLA associations, somatic loss of HLA expression, and clinical outcomes in immune aplastic anemiapmc.ncbi.nlm.nih.gov
22. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitropubmed.ncbi.nlm.nih.gov
23. Expression and modulation of cellular receptors for interferon-gamma, tumour necrosis factor, and Fas on human bone marrow CD34+ cellspubmed.ncbi.nlm.nih.gov
24. Aplastic anemia: presence in human bone marrow of cells that suppress myelopoiesispubmed.ncbi.nlm.nih.gov
25. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemiapubmed.ncbi.nlm.nih.gov
26. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuriapubmed.ncbi.nlm.nih.gov
27. When does a PNH clone have clinical significance?pmc.ncbi.nlm.nih.gov
28. Aplastic Anemia & Myelodysplastic Syndromes - NIDDKniddk.nih.gov
29. Aplastic anemia - Symptoms and causes - Mayo Clinicmayoclinic.org
30. Anemia - What Is Anemia? | NHLBI, NIHnhlbi.nih.gov
31. Anemia - Symptoms | NHLBI, NIHnhlbi.nih.gov
32. Aplastic Anemia - Together by St. Jude™together.stjude.org
33. Definition & Facts for Aplastic Anemia & Myelodysplastic Syndromes - NIDDKniddk.nih.gov
34. Thrombocytopenia (Low Platelets) - Together by St. Jude™together.stjude.org
35. Your Guide to Anemianhlbi.nih.gov
36. Anemia - Causes and Risk Factors | NHLBI, NIHnhlbi.nih.gov
37. Cancer, Infection, and Sepsiscdc.gov
38. Aplastic Anemia Disease Definitionhematology.org
39. Modified Delphi panel consensus recommendations for management of severe aplastic anemiapmc.ncbi.nlm.nih.gov
40. Treatment of Aplastic Anemia & Myelodysplastic Syndromesniddk.nih.gov
41. American Society of Hematology 2026 guidelines for the diagnosis and management of severe and very severe acquired aplastic anemiapmc.ncbi.nlm.nih.gov
42. DailyMed - CYCLOSPORINE capsule, liquid filleddailymed.nlm.nih.gov
43. Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 studypmc.ncbi.nlm.nih.gov
44. Treatments for Blood Disorders - Treatments for Blood Disordersnhlbi.nih.gov
45. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendationsnature.com
46. The EBMT Handbookebmt.org
47. Conditioning - The EBMT Handbook - NCBI Bookshelfncbi.nlm.nih.gov
48. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groupshaematologica.org
49. Documentation of Engraftment and Chimerism After HCTncbi.nlm.nih.gov
50. Engraftment, Graft Failure, and Rejectionncbi.nlm.nih.gov
51. Role of Umbilical Cord Blood Transplantation - The EBMT Handbook - NCBI Bookshelfncbi.nlm.nih.gov
52. Eltrombopag and improved hematopoiesis in refractory aplastic anemiapubmed.ncbi.nlm.nih.gov
53. Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational studynature.com
54. Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone-marrow infusionspubmed.ncbi.nlm.nih.gov
55. Human autoimmunity at single cell resolution in aplastic anemia before and after effective immunotherapypubmed.ncbi.nlm.nih.gov
56. Human autoimmunity at single cell resolution in aplastic anemia before and after effective immunotherapypmc.ncbi.nlm.nih.gov
57. Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemiapmc.ncbi.nlm.nih.gov